• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疫苗:设计和测试的基本原则。

Vaccines: Underlying Principles of Design and Testing.

机构信息

Department of Microbiology & Immunology, UNC-Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.

UNC HIV Cure Center, UNC-Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.

出版信息

Clin Pharmacol Ther. 2021 Apr;109(4):987-999. doi: 10.1002/cpt.2207. Epub 2021 Mar 11.

DOI:10.1002/cpt.2207
PMID:33705574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8048882/
Abstract

In this paper, we review the key elements that should be considered to take a novel vaccine from the laboratory through to licensure in the modern era. This paper is divided into four sections. First, we discuss the host immune responses that we engage with vaccines. Second, we discuss how in vivo and in vitro studies can inform vaccine design. Third, we discuss different vaccine modalities that have been licensed or are in testing in humans. Last, we overview the basic principles of vaccine approvals. Throughout we provide real-world examples of vaccine development against infectious diseases, including coronavirus disease 2019 (COVID-19).

摘要

在本文中,我们回顾了从实验室到现代时代获得新型疫苗所应考虑的关键要素。本文分为四个部分。首先,我们讨论了我们所涉及的宿主免疫反应。其次,我们讨论了体内和体外研究如何为疫苗设计提供信息。第三,我们讨论了已经获得许可或正在人体测试的不同疫苗模式。最后,我们概述了疫苗批准的基本原则。在整个过程中,我们提供了针对传染病(包括 2019 年冠状病毒病(COVID-19))的疫苗开发的实际示例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90f6/8206848/972c5d82ad17/CPT-109-987-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90f6/8206848/972c5d82ad17/CPT-109-987-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90f6/8206848/972c5d82ad17/CPT-109-987-g001.jpg

相似文献

1
Vaccines: Underlying Principles of Design and Testing.疫苗:设计和测试的基本原则。
Clin Pharmacol Ther. 2021 Apr;109(4):987-999. doi: 10.1002/cpt.2207. Epub 2021 Mar 11.
2
Principles of Vaccine Licensure, Approval, and Recommendations for Use.疫苗上市许可、审批和使用建议的原则
Mayo Clin Proc. 2020 Mar;95(3):600-608. doi: 10.1016/j.mayocp.2019.11.002. Epub 2020 Feb 13.
3
COVID-19 vaccines and herd immunity: Perspectives, challenges and prospects.COVID-19 疫苗与群体免疫:观点、挑战与展望。
Malays J Pathol. 2021 Aug;43(2):203-217.
4
Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.新兴和再现病毒性传染病疫苗研发的成功率和时间表。
Ann Intern Med. 2021 Mar;174(3):326-334. doi: 10.7326/M20-5350. Epub 2020 Nov 24.
5
Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee.从部分疫苗研发回顾中汲取的经验教训。国家疫苗咨询委员会。
Pediatrics. 1999 Oct;104(4 Pt 1):942-50.
6
The Regulatory Evaluation of Vaccines for Human Use.人类用疫苗的监管评估
Methods Mol Biol. 2016;1404:773-787. doi: 10.1007/978-1-4939-3389-1_51.
7
The path forward.前进的道路。
Vaccine. 2015 Jun 8;33 Suppl 2:B60-3. doi: 10.1016/j.vaccine.2015.01.087.
8
Food and Drug Administration regulation and evaluation of vaccines.食品和药物管理局对疫苗的监管和评估。
Pediatrics. 2011 May;127 Suppl 1:S23-30. doi: 10.1542/peds.2010-1722E. Epub 2011 Apr 18.
9
Modes of Action for Mucosal Vaccine Adjuvants.黏膜疫苗佐剂的作用方式
Viral Immunol. 2017 Jul/Aug;30(6):463-470. doi: 10.1089/vim.2017.0026. Epub 2017 Apr 24.
10
Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.疫苗佐剂:在疫苗免疫原性中的作用及作用机制
Drug Discov Today. 2003 Oct 15;8(20):934-43. doi: 10.1016/s1359-6446(03)02864-2.

本文引用的文献

1
An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.一种工程化受体结合域可提高多价SARS-CoV-2疫苗的免疫原性。
mBio. 2021 May 11;12(3):e00930-21. doi: 10.1128/mBio.00930-21.
2
Moderna COVID vaccine becomes second to get US authorization.莫德纳新冠疫苗成为第二种获得美国授权的疫苗。
Nature. 2020 Dec 18. doi: 10.1038/d41586-020-03593-7.
3
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
ChAdOx1 nCoV-19 疫苗(阿斯利康)对 SARS-CoV-2 的安全性和有效性:巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
4
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.严重急性呼吸综合征冠状病毒2刺突糖蛋白的结构、功能及抗原性
Cell. 2020 Dec 10;183(6):1735. doi: 10.1016/j.cell.2020.11.032.
5
The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.免疫实践咨询委员会关于分配 COVID-19 疫苗初始供应的临时建议-美国,2020 年。
MMWR Morb Mortal Wkly Rep. 2020 Dec 11;69(49):1857-1859. doi: 10.15585/mmwr.mm6949e1.
6
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.嵌合血凝素基通用流感病毒疫苗方法在一项随机、安慰剂对照的 I 期临床试验中诱导了广泛和持久的免疫。
Nat Med. 2021 Jan;27(1):106-114. doi: 10.1038/s41591-020-1118-7. Epub 2020 Dec 7.
7
Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.在消灭脊灰病毒后时代,不同灭活脊灰病毒疫苗接种方案的安全性和免疫原性:一项随机、开放标签、多中心、3 期、非劣效性试验。
Lancet Infect Dis. 2021 Apr;21(4):559-568. doi: 10.1016/S1473-3099(20)30555-7. Epub 2020 Oct 23.
8
Correlates of protection against SARS-CoV-2 in rhesus macaques.恒河猴中 SARS-CoV-2 保护作用的相关因素。
Nature. 2021 Feb;590(7847):630-634. doi: 10.1038/s41586-020-03041-6. Epub 2020 Dec 4.
9
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
10
The continued advance of vaccine adjuvants - 'we can work it out'.疫苗佐剂的不断进步——“我们可以解决它”。
Semin Immunol. 2020 Aug;50:101426. doi: 10.1016/j.smim.2020.101426. Epub 2020 Nov 27.